METTL16 in cancer: Roles and regulatory mechanisms.

Kangjie Qiu, Shuxin Zhong, Jinyi Liu, Weini Li, Cunte Chen, Yangqiu Li, Chengwu Zeng

Abstract readReview

In one paragraph

Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

METTL16 promotes colorectal cancer progression and CD8Medical oncology (Northwood, London, England) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kangjie QiuKey Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.

Shuxin ZhongKey Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.

Jinyi LiuGuangzhou First People's Hospital, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510700, China.

Weini LiCedars-Sinai Cancer Institute, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Cunte ChenGuangzhou First People's Hospital, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510700, China.

Yangqiu LiKey Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.

Chengwu ZengKey Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The regulation of gene expression is pivotal in cancer development, with increasing emphasis on epigenetic modifications such as RNA methylation. N6-methyladenosine (m

Indexed as

Cancerm6AMETTL16RNA methylationSAM metabolism

Identifiers

PMID41459114

DOI10.1016/j.gendis.2025.101758

PMCPMC12741382

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.